Radius Health Inc (NASDAQ:RDUS) was up 3.1% during mid-day trading on Tuesday . The company traded as high as $57.20 and last traded at $56.83, with a volume of 745,302 shares traded. The stock had previously closed at $55.11.

A number of equities research analysts have issued reports on RDUS shares. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a research report on Monday, August 8th. Maxim Group cut Radius Health from a “hold” rating to a “sell” rating and set a $24.00 target price for the company. in a research report on Thursday, August 4th. Canaccord Genuity set a $85.00 price target on Radius Health and gave the stock a “buy” rating in a report on Monday. Cowen and Company reiterated a “buy” rating on shares of Radius Health in a report on Thursday, August 4th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and set a $70.00 price target on shares of Radius Health in a report on Friday, August 5th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $61.73.

The company has a 50-day moving average price of $54.72 and a 200 day moving average price of $40.96. The firm’s market capitalization is $2.44 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/radius-health-inc-rdus-trading-up-3-1.html

Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by $0.06. During the same quarter last year, the business earned ($0.61) earnings per share. Equities research analysts anticipate that Radius Health Inc will post ($3.95) EPS for the current year.

Large investors have recently made changes to their positions in the stock. Norges Bank purchased a new stake in shares of Radius Health during the fourth quarter worth about $23,721,000. Rhenman & Partners Asset Management AB purchased a new stake in shares of Radius Health during the first quarter worth about $3,301,000. Apex Capital Management raised its stake in shares of Radius Health by 7.4% in the first quarter. Apex Capital Management now owns 443,861 shares of the biopharmaceutical company’s stock worth $13,955,000 after buying an additional 30,436 shares in the last quarter. Verde Servicos Internacionais S.A. purchased a new stake in shares of Radius Health during the first quarter worth about $1,535,000. Finally, Teachers Advisors Inc. raised its stake in shares of Radius Health by 1.9% in the first quarter. Teachers Advisors Inc. now owns 50,805 shares of the biopharmaceutical company’s stock worth $1,597,000 after buying an additional 926 shares in the last quarter. 99.91% of the stock is currently owned by institutional investors and hedge funds.

About Radius Health

Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.

5 Day Chart for NASDAQ:RDUS

Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.